Search Results for: Clinical Roundup
-
Clinic Roundup
Data demonstrated that EBI-005 was safe and well tolerated in both preclinical testing and in a clinical Phase Ia study in healthy volunteers...These data led to Eleven's Phase Ib clinical study of EBI-005 in subjects with dry eye disease, with top-line data from the Phase Ib study expected in the second half of 2013BioWorld Today | Thursday, May 9, 2013 -
Lumena Large: $23M Series A Funds Phase II Cholestatic Bid
The drug has gone through 12 clinical trials in more than 1,400 subjects already, showing that it knocks down serum bile acid levels safely...Also in the pipeline: Lumena has licensed the patent rights and a package of clinical and non-clinical data for LUM002, another inhibitor of ASBT, also previously in development at the Phase I stage as a cholesterol-lowering agent by Paris-based Sanofi SA...Lumena plans to complete the Phase I clinical program of LUM002 in healthy volunteers later this yearBy Randy Osborne | BioWorld Today | Thursday, May 9, 2013 -
Increased Demand for Pediatric Trials Leads to BIO Initiative
Using ViS' online analytics platform, the initiative is expected to reduce the barriers to global pediatric clinical research by helping drugmakers identify patients, enabling streamlined trial enrollment and site selection...Eventually, it could be used to find research centers, staffing talent and other resources needed to conduct a pediatric clinical trial in a specific region...To get FDA authorization to charge for an investigative drug or for an unapproved use of an approved drug in a clinicalBy Mari Serebrov | BioWorld Today | Thursday, May 9, 2013 -
Pharma: Clinic Roundup
The study, dubbed Gammaglobulin Alzheimer's Partnership, was conducted in collaboration with the Alzheimer's Disease Cooperative Study, a clinical trial consortium supported by the National Institute on AgingBioWorld Today | Wednesday, May 8, 2013 -
Latest Astellas, Drais Spinout, Tacurion Launches with $15M
spun out in 2011, and Flexion Therapeutics Inc., of Woburn, Mass., founded by veterans of Eli Lilly and Co.'s Chorus division to advance abandoned early clinical programs through proof of concept. (See BioWorld Today, Feb. 1, 2010, and July 28, 2011.) The $15 million investment in Tacurion will support a Phase II proof-of-concept trial for the drug that should take 18 months to two years to complete...Portola, which seeks a listing on Nasdaq under the ticker "PTLA," filed for the IPO last monthBy Catherine Shaffer | BioWorld Today | Wednesday, May 8, 2013 -
More States Are Saying No to Biosimilar Safeguards
An interchangeable biologic is expected to produce the same clinical results as the reference drug in any given patient...CER Projects Funded The Patient-Centered Outcomes Research Institute approved 51 new awards, totaling $88.6 million over three years, to fund comparative clinical effectiveness research (CER) projects that fall under the first four areas of its research agenda...Editor's note: For a copy of BioWorld's new biosimilars report, please contact the BioWorld Data account managers forBy Mari Serebrov | BioWorld Today | Wednesday, May 8, 2013 -
Clinic Roundup
CytRx Corp., of Los Angeles, said the independent data safety monitoring committee overseeing the company's international Phase IIb trial with aldoxorubicin as a first-line treatment for patients with late-stage metastatic soft tissue sarcoma has recommended conducting the clinical trial through completion...The NH004-3 clinical trial is a double-blind, placebo-controlled, randomized, crossover, multicenter study comparing NH004 and placebo thin films in Parkinson's disease patient complaining ofBioWorld Today | Tuesday, May 7, 2013 -
Arrowhead Bolsters Balance Sheet, Adds $36M for Pipeline
shored up its balance sheet in a $36 million private offering to advance pipeline work, including planned clinical trials of ARC-520, an RNAi-based drug in chronic HBV infection...Shares of Supernus (NASDAQ:SUPN) lost 3 cents Monday to close at $5.12.By Jennifer Boggs | BioWorld Today | Tuesday, May 7, 2013 -
Clinic Roundup
clinical trials where a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugsBioWorld Today | Monday, May 6, 2013 -
Galapagos Lands $71M from Stoked U.S. Investors
The first clinical trials of the drug, GLPG1790, are expected to start within the next year...On Friday, the company's NASDAQ-listed American depository shares (NASDAQ:PRAN) gained 1 cent, closing at $2.27.By Nuala Moran | BioWorld Today | Monday, May 6, 2013 -
Arena Yanks MAA, Falls on Belviq Launch Delay in U.S.
The drug was included in a recent diabetes management report from the American Association of Clinical EndocrinologistsBy Jennifer Boggs | BioWorld Today | Monday, May 6, 2013 -
Celator Pharmaceuticals Raises $32.5M for Phase III AML Trial
The trial, which will enroll 300 patients, is based on results from a Phase IIb study in newly diagnosed AML patients, 60-75, presented at the American Society of Clinical Oncology conference in 2011...The exercise of the overallotment option brings the total gross proceeds from the offering to $10.75 million. (See BioWorld Today, May 1, 2013.)By Staff Reports | BioWorld Today | Thursday, May 2, 2013 -
Clinic Roundup
The open-label trial will randomize 20 postmenopausal women with estrogen receptor-positive disease who have responded previously to hormone therapy to receive 9 mg of enobosarm once daily until they show clinical progression or have completed 336 days of treatment...The primary endpoint is clinical benefit, which will be assessed at six months...RepliCel Life Sciences Inc., of Vancouver, British Columbia, said it started clinical development of an autologous cell therapy for the treatment of aBioWorld Today | Wednesday, May 1, 2013 -
Phase III-Ready Anticoagulant Awaits Cash from Regado IPO
Scioderm is advancing SD-101, a topical cream with a unique mechanism of action, into clinical development in epidermolysis bullosa (EB), a rare genetic condition that results in extremely fragile skin that blisters and tears easily...In an open-label Phase II study conducted in children with simplex, recessive dystrophic EB or junctional EB, SD-101 application resulted in complete closure of 88 percent of target chronic lesions within one month.By Randy Osborne | BioWorld Today | Wednesday, May 1, 2013 -
ECCMID Roundup
The following data were reported from European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Berlin...Trius Therapeutics Inc., of San Diego, announced a range of clinical data for the experimental antibiotic tedizolid phosphate (TR-701) and a presentation on linezolid-resistant strain of bacteria...The results of a separate clinical cardiovascular safety study showed that tedizolid was not associated with heart beat abnormalities at up to six times its effective doseBioWorld Today | Tuesday, April 30, 2013 -
Epizyme Files for IPO, Aims for $69M for Epigenetics Platform
The company filed to go public earlier this month, aiming to raise $86.3 million to support clinical work in multiple sclerosis, inflammatory bowel disease and allergic/immune-mediated disorders...The funding allowed ReXceptor to enter a formal partnership with C2N Diagnostics, which will assist the company with the initiation and coordination of the clinical trial of an AD program licensed from Case Western's Technology Transfer Office and based on discoveries that bexarotene, a medication sold atBy Jennifer Boggs | BioWorld Today | Monday, April 29, 2013 -
CBO: Key to Innovation is Making it a National Priority
When it comes to biopharma, the development cost for one drug can be hundreds of millions of dollars, depending on the number and size of clinical trials the FDA requires...We would like to see CMS use any flexibility that exists to implement the cuts in such a way that the core mission of the agency – to provide care to beneficiaries – is retained and protected," the lawmakers said in a recent letter to CMS.By Mari Serebrov | BioWorld Today | Thursday, April 25, 2013 -
Clinic Roundup
Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said the Journal of Nuclear Medicine published the results from a clinical trial of NAV4694 in healthy subjects and those with diagnosed forms of dementiaBioWorld Today | Monday, April 22, 2013 -
ActoGeniX Series B to Move IBD Program to IND Stage
AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...Shares of Northwest (NASDAQ:NWBO) fell 13 cents to close Thursday at $3.77.By Marie Powers | BioWorld Today | Friday, April 19, 2013 -
Auris Medical Gets $51M for Hearing Disorder Drugs
Proceeds will be used to advance its gene therapy product for congestive heart failure into clinical development...BofA Merrill Lynch, Barclays and Leerink Swann acted as joint book-running managers, while Stifel and Piper Jaffray served as co-managers. (See BioWorld Today, April 2, 2013.)By Cormac Sheridan | BioWorld Today | Wednesday, April 17, 2013
Category
Current Filters
- xNOT stem cells
Related Keywords
Categories
- x BioWorld Today (2175)
- x BioWorld International (48)
- x Bio Perspectives (4)
- x BioWorld Insight (1)
- x State of the Industry Report (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.